PURE Bioscience, developer of technology-based bioscience products addressing global health challenges such as Staph (MRSA), has named Peter C. Wulff as CFO, effective November 5, 2012.
Wulff has 25 years of financial and operating management experience, including more than 12 years as a senior-level executive in the life science industry. Wulff most recently served as CFO, vice president, treasurer, and senior vice president of Strategic Initiatives for Alphatec Holdings Inc. (ATEC) and its subsidiary, Alphatec Spine, a developer and manufacturer of spinal implant products.
“Peter has a proven ability to manage rapid growth and oversee the development of successful new products and technologies. We are confident that his expertise will be of immediate benefit across our business, including optimizing our many current opportunities and creating new growth initiatives,” Michael L. Krall, president and CEO of PURE Bioscience stated in the press release.
Wulff’s resume also includes his tenure as executive vice president and CFO for Artes Medical, where he led the company’s IPO and introduction of FDA-approved products. He also served as CFO for medical device company CryoCor, as well as CFO and treasurer of Natural Alternatives International, a manufacturer of nutritional products.
Wulff has a bachelor’s degree in economics and Germanic languages and an MBA in finance from Indiana University.
For more information visit www.purebio.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
